SuppreMol in-licenses anti-IL-3 antibody targeting early Rheumatoid Arthritis
Martinsried – Germany’s autoimmunity specialist SuppreMol GmbH has in-licensed an anti interleukin 3 (IL-3) antibody in preclinical development from University of Regensburg, that opens up early treatment of rheumatoid arthritis (RA). In mice, the patented mouse antibody prevented disease exacerbation. IL-3 seems to play also an important role in the onset of RA in humans, an autoimmune disease characterised by a chronic inflammation of the joints and other organs. In previous studies, the academic group under Prof. Matthias Mack found the cytokine was overexpressed in patients with RA. Molecules that block interaction with of the cytokine with its receptor may be an alternative for the 20% of RA patients that only poorly respond to current RA therapies with methotrexate or TNF-alpha blockers such as Humira (Abbott Laboratories). IL-3 blockers are also under investigation by Indian researchers. With the deal, Suppremol expands its autoimmunity pipeline of soluble Fc gamma receptors (sFcRs). The firm’s lead candidate SM101 is a recombinant, soluble, non-glycosylated version of the Fc receptor IIb that blocks triggering of Fc receptors on the surface of immune cells.
The orphan drug candidate is currently being developed in Primary Immune Thrombocytopenia (ITP) but may also have potential in Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and other autoimmune diseases.